Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Graft-versus-host Disease (GvHD)
100%
Human Mesenchymal Stem Cells (hMSCs)
100%
Murine Model
100%
Human MSCs
100%
Immunosuppressive Mechanisms
100%
Donor T Cell
60%
Quantitative PCR
40%
Lymphoid Organs
40%
CCL3
40%
Bone Marrow Cells
40%
Inflammatory Cytokines
40%
Survival Rate
40%
C-C Chemokine Receptor Type 5 (CCR5)
40%
RANTES
40%
Mesenchymal Stromal Cells
40%
Disease Score
40%
Immunosuppression
40%
CXCL9
40%
T-cell Alloreactivity
40%
CXCR3
40%
CCR7
40%
Inducible Nitric Oxide Synthase
20%
Lymphocytes
20%
Western Blotting
20%
Phosphorylation
20%
Flow Cytometry
20%
Treatment Group
20%
Pathological Changes
20%
Negative Control
20%
Transplantation
20%
Histological Analysis
20%
Nitrous Oxide
20%
In Vivo Model
20%
C57BL
20%
CCL5
20%
Cellular Mechanisms
20%
In Vivo Imaging
20%
Positive Control
20%
CD4+ T
20%
EphB2
20%
Immune Dysregulation
20%
Cytokine Suppression
20%
EphrinB2
20%
T Cell Depletion
20%
Immunosuppressive Function
20%
Immunology and Microbiology
Immunosuppressive Drug
100%
Graft-Versus-Host Disease
100%
Mesenchymal Stem Cell
100%
T Cell
60%
Quantitative Reverse Transcription Polymerase Chain Reaction
40%
Alloimmunity
40%
Immunosuppression
40%
Lymphoid Organ
40%
Survival Rate
40%
CCL3
40%
CCR5
40%
RANTES
40%
Target Tissue
40%
CXCL9
40%
CXCR3
40%
Western Blot
20%
Immune Dysregulation
20%
Inflammatory Cytokine
20%
Proinflammatory Cytokine
20%
ELISA
20%
Bone Marrow Cell
20%
CCL5
20%
Tissue Section
20%
CD4+ T Lymphocyte
20%
Medicine and Dentistry
Mesenchymal Stem Cell
100%
Immunosuppressive Drug
100%
Graft Versus Host Reaction
100%
T Cell
60%
Survival Rate
40%
Immunosuppressive Treatment
40%
Quantitative Reverse Transcription Polymerase Chain Reaction
40%
Lymphoid Organ
40%
RANTES
40%
Target Tissue
40%
Alloimmunity
40%
Cytokine
20%
Flow Cytometry
20%
Enzyme Linked Immunosorbent Assay
20%
Western Blot
20%
Bone Marrow Cell
20%
C57BL/6
20%
Nitrous Oxide
20%
CD4+ T Lymphocyte
20%
Ephrin B2
20%
Inflammatory Cytokine
20%
Immune Dysregulation
20%
Treatment Group
20%